Biocartis, an innovative molecular diagnostics company, today announces the launch of its second liquid biopsy assay, the Idylla™ ctKRAS Mutation Assay (Research Use Only, RUO), which was developed in partnership with the leading science and technology company Merck1 on Biocartis’ molecular diagnostics platform Idylla™.
Biocartis is pleased to add a new Idylla EGFR (Epidermal Growth Factor Receptor) Mutation Assay (Research Use Only) to their core oncology menu, that now covers most known and used oncology biomarkers.
Idylla™, Biocartis’ fully automated, real-time PCR based molecular diagnostics system, is designed to offer fast and easy access to clinical molecular diagnostic information, anywhere and anytime.
Introducing Biocartis Idylla – BRAF molecular results in as little as 90 minutes.
About 50 percent of all melanomas harbor mutations in the BRAF oncogene. Idylla™ BRAF Mutation Test detects BRAF mutations directly from FFPE tissue sections in 90 minutes with less than 2 minutes hands-on time.
Press Release: Mechelen, Belgium, 27 June 2018
PRESS RELEASE: 28 August 2018
Mechelen, Belgium, 28 August 2018 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it has obtained exclusive worldwide license rights for highly innovative EGFR ectodomain mutations that have shown to determine response to targeted therapy for patients with metastatic colorectal cancer1 (mCRC).
The Idylla™ MSI Assay provides information on the MSI 1 status2,3,4 (i.e. MSI-High or Microsatellite stable) of a tumour within approximately 150 minutes from just one slice of FFPE5 tumour tissue, without requiring a reference sample.
Abacus dx would like to update you with the latest products from Asuragen.
Abacus dx would like to update you with the latest products from Asuragen.